The price of NeoGenomics Inc. (NASDAQ: NEO) closed at $17.91 in the last session, down -2.29% from day before closing price of $18.33. In other words, the price has decreased by -$0.42 from its previous closing price. On the day, 615755 shares were traded. NEO stock price reached its highest trading level at $18.83 during the session, while it also had its lowest trading level at $17.83.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
Ratios:
We take a closer look at NEO’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 6.50 and its Current Ratio is at 6.80. In the meantime, Its Debt-to-Equity ratio is 0.55 whereas as Long-Term Debt/Eq ratio is at 0.55.
Upgrades & Downgrades
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NEO now has a Market Capitalization of 2.51B and an Enterprise Value of 2.68B. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.35 while its Price-to-Book (P/B) ratio in mrq is 2.30. Its current Enterprise Value per Revenue stands at 5.06 whereas that against EBITDA is -40.71.
Stock Price History:
Over the past 52 weeks, NEO has reached a high of $20.54, while it has fallen to a 52-week low of $6.00. The 50-Day Moving Average of the stock is 16.73, while the 200-Day Moving Average is calculated to be 12.30.
Shares Statistics:
According to the various share statistics, NEO traded on average about 1.30M shares per day over the past 3-months and 1.03M shares per day over the past 10 days. A total of 125.03M shares are outstanding, with a floating share count of 122.24M. Insiders hold about 0.80% of the company’s shares, while institutions hold 90.80% stake in the company. Shares short for NEO as of Apr 27, 2023 were 7.08M with a Short Ratio of 7.08M, compared to 5.83M on Mar 30, 2023. Therefore, it implies a Short% of Shares Outstanding of 5.55% and a Short% of Float of 7.83%.
Earnings Estimates
The company has 13 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.12 for the current quarter, with a high estimate of -$0.08 and a low estimate of -$0.23, while EPS last year was -$0.16. The consensus estimate for the next quarter is -$0.11, with high estimates of -$0.08 and low estimates of -$0.26.
Analysts are recommending an EPS of between -$0.3 and -$0.89 for the fiscal current year, implying an average EPS of -$0.39. EPS for the following year is -$0.24, with 13 analysts recommending between -$0.11 and -$0.66.
Revenue Estimates
According to 12 analysts, the current quarter’s revenue is expected to be $137.42M. It ranges from a high estimate of $141.9M to a low estimate of $133.3M. As of the current estimate, NeoGenomics Inc.’s year-ago sales were $125.07M, an estimated increase of 9.90% from the year-ago figure. For the next quarter, 12 analysts are estimating revenue of $140.05M, an increase of 15.20% over than the figure of $9.90% in the same quarter last year. There is a high estimate of $141.9M for the next quarter, whereas the lowest estimate is $137.09M.
A total of 13 analysts have provided revenue estimates for NEO’s current fiscal year. The highest revenue estimate was $570M, while the lowest revenue estimate was $559.75M, resulting in an average revenue estimate of $562.42M. In the same quarter a year ago, actual revenue was $509.73M, up 10.30% from the average estimate. Based on 13 analysts’ estimates, the company’s revenue will be $608.45M in the next fiscal year. The high estimate is $615M and the low estimate is $599.8M. The average revenue growth estimate for next year is up 8.20% from the average revenue estimate for this year.
